Specific glycogen synthase kinase-3 inhibition reduces neuroendocrine markers and suppresses neuroblastoma cell growth

Cancer Biology and Therapy

Volumn 15, Issue 5, 2014, Pages 510-515

  Carter, Yvette M ^a   Kunnimalaiyaan, Selvi ^a,b   Chen, Herbert ^a   Gamblin, T Clark ^b   Kunnimalaiyaan, Muthusamy ^a,b  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Apoptosis; AR A014418; GSK3; Neuroblastoma

Indexed keywords

1 (4 METHOXYBENZYL) 3 (5 NITRO 2 THIAZOLYL)UREA; ACHAETE SCUTE COMPLEX LIKE1; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; BETA CATENIN; CHROMOGRANIN A; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; GLYCOGEN SYNTHASE KINASE 3ALPHA; GLYCOGEN SYNTHASE KINASE 3BETA; SMALL INTERFERING RNA; TUMOR MARKER; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; ASCL1 PROTEIN, HUMAN; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 ALPHA; GLYCOGEN SYNTHASE KINASE 3 BETA; N-(4-METHOXYBENZYL)-N'-(5-NITRO-1,3-THIAZOL-2-YL)UREA; THIAZOLE DERIVATIVE; TYROSINE; UREA;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; NEUROBLASTOMA CELL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TREATMENT DURATION; TUMOR LOCALIZATION; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BONE MARROW CANCER; DRUG EFFECTS; METABOLISM; NEUROBLASTOMA; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; BIOMARKERS, TUMOR; BONE MARROW NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMOGRANIN A; GLYCOGEN SYNTHASE KINASE 3; HUMANS; NEUROBLASTOMA; PHOSPHORYLATION; THIAZOLES; TYROSINE; UREA;

EID: 84899842513     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.28015     Document Type: Article

References (29)

1. Maris JM. Recent advances in neuroblastoma. N Engl J Med 2010; 362:2202-11; PMID:20558371; http://dx.doi.org/10.1056/NEJMra0804577
2. Zage PE, Nolo R, Fang W, Stewart J, Garcia- Manero G, Zweidler-McKay PA. Notch pathway activation induces neuroblastoma tumor cell growth arrest. Pediatr Blood Cancer 2012; 58:682-9; PMID:21744479; http://dx.doi.org/10.1002/pbc.23202
3. Wojtalla A, Salm F, Christiansen DG, Cremona T, Cwiek P, Shalaby T, Gross N, Grotzer MA, Arcaro A. Novel agents targeting the IGF-1R/PI3K pathway impair cell proliferation and survival in subsets of medulloblastoma and neuroblastoma. PLoS One 2012; 7:e47109; PMID:23056595; http://dx.doi.org/10.1371/journal.pone. 0047109
4. Franks LM, Bollen A, Seeger RC, Stram DO, Matthay KK. Neuroblastoma in adults and adolescents: an indolent course with poor survival. Cancer 1997; 79:2028-35; PMID:9149032; http://dx.doi.org/10.1002/(SICI)1097-0142(19970515)79: 10<2028::AIDCNCR26>3.0.CO;2-V (Pubitemid 27200389)
5. Kushner BH, Kramer K, LaQuaglia MP, Modak S, Cheung NK. Neuroblastoma in adolescents and adults: the Memorial Sloan-Kettering experience. Med Pediatr Oncol 2003; 41:508-15; PMID:14595707; http://dx.doi.org/10.1002/mpo.10273 (Pubitemid 37386067)
6. Cianfarani S, Rossi P. Neuroblastoma and insulin- like growth factor system. New insights and clinical perspectives. Eur J Pediatr 1997; 156:256-61; PMID:9128806; http://dx.doi.org/10.1007/s004310050595 (Pubitemid 27142142)
7. Gilbertson R. Paediatric embryonic brain tumours. biological and clinical relevance of molecular genetic abnormalities. Eur J Cancer 2002; 38:675-85; PMID:11916550; http://dx.doi.org/10.1016/S0959-8049(01)00315-X (Pubitemid 34251391)
8. Ho R, Eggert A, Hishiki T, Minturn JE, Ikegaki N, Foster P, Camoratto AM, Evans AE, Brodeur GM. Resistance to chemotherapy mediated by TrkB in neuroblastomas. Cancer Res 2002; 62:6462-6; PMID:12438236 (Pubitemid 35364107)
9. Rikhof B, de Jong S, Suurmeijer AJ, Meijer C, van der Graaf WT. The insulin-like growth factor system and sarcomas. J Pathol 2009; 217:469-82; PMID:19148905; http://dx.doi.org/10.1002/path.2499
10. Wechsler-Reya R, Scott MP. The developmental biology of brain tumors. Annu Rev Neurosci 2001; 24:385-428; PMID:11283316; http://dx.doi.org/10.1146/ annurev.neuro.24.1.385 (Pubitemid 32695234)
11. Katso R, Okkenhaug K, Ahmadi K, White S, Timms J, Waterfield MD. Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu Rev Cell Dev Biol 2001; 17:615-75; PMID:11687500; http://dx.doi.org/10.1146/annurev.cellbio.17.1.615 (Pubitemid 33096187)
12. Vanhaesebroeck B, Guillermet-Guibert J, Graupera M, Bilanges B. The emerging mechanisms of isoform- specific PI3K signalling. Nat Rev Mol Cell Biol 2010; 11:329-41; PMID:20379207; http://dx.doi.org/10.1038/nrm2882
13. Vanhaesebroeck B, Vogt PK, Rommel C. PI3K: from the bench to the clinic and back. Curr Top Microbiol Immunol 2010; 347:1-19; PMID:20549473; http://dx.doi.org/10.1007/82-2010-65
14. Carter Y, Jaskula-Sztul R, Chen H, Mazeh H. Signaling pathways as specific pharmacologic targets for neuroendocrine tumor therapy: RET, PI3K, MEK, growth factors, and Notch. Neuroendocrinology 2013; 97:57-66; PMID:22343668; http://dx.doi.org/10.1159/000335136
15. Luo J. Glycogen synthase kinase 3beta (GSK3beta) in tumorigenesis and cancer chemotherapy. Cancer Lett 2009; 273:194-200; PMID:18606491; http://dx.doi.org/10.1016/j.canlet.2008.05.045
16. Martinez A. Preclinical efficacy on GSK-3 inhibitors: towards a future generation of powerful drugs. Med Res Rev 2008; 28:773-96; PMID:18271054; http://dx.doi.org/10.1002/med.20119
17. Dickey A, Schleicher S, Leahy K, Hu R, Hallahan D, Thotala DK. GSK-3β inhibition promotes cell death, apoptosis, and in vivo tumor growth delay in neuroblastoma Neuro-2A cell line. J Neurooncol 2011; 104:145-53; PMID:21161565; http://dx.doi.org/10.1007/s11060-010-0491-3
18. Pizarro JG, Folch J, Esparza JL, Jordan J, Pallàs M, Camins A. A molecular study of pathways involved in the inhibition of cell proliferation in neuroblastoma B65 cells by the GSK-3 inhibitors lithium and SB-415286. J Cell Mol Med 2009; 13(9B):3906-17; PMID:18624766; http://dx.doi.org/10.1111/j.1582- 4934.2008.00389.x
19. Ngok-Ngam P, Watcharasit P, Thiantanawat A, Satayavivad J. Pharmacological inhibition of GSK3 attenuates DNA damage-induced apoptosis via reduction of p53 mitochondrial translocation and Bax oligomerization in neuroblastoma SH-SY5Y cells. Cell Mol Biol Lett 2013; 18:58-74; PMID:23161404; http://dx.doi.org/10.2478/s11658-012-0039-y
20. Ougolkov AV, Fernandez-Zapico ME, Savoy DN, Urrutia RA, Billadeau DD. Glycogen synthase kinase-3beta participates in nuclear factor kappaBmediated gene transcription and cell survival in pancreatic cancer cells. Cancer Res 2005; 65:2076-81; PMID:15781615; http://dx.doi.org/10.1158/0008-5472.CAN-04-3642 (Pubitemid 40490111)
21. Wilson W 3rd, Baldwin AS. Maintenance of constitutive IkappaB kinase activity by glycogen synthase kinase-3alpha/beta in pancreatic cancer. Cancer Res 2008; 68:8156-63; PMID:18829575; http://dx.doi.org/10.1158/0008-5472.CAN-08- 1061
22. Pinchot SN, Adler JT, Luo Y, Ju J, Li W, Shen B, Kunnimalaiyaan M, Chen H. Tautomycin suppresses growth and neuroendocrine hormone markers in carcinoid cells through activation of the Raf-1 pathway. Am J Surg 2009; 197:313-9; PMID:19245907; http://dx.doi.org/10.1016/j.amjsurg.2008.10.007
23. Adler JT, Cook M, Luo Y, Pitt SC, Ju J, Li W, Shen B, Kunnimalaiyaan M, Chen H. Tautomycetin and tautomycin suppress the growth of medullary thyroid cancer cells via inhibition of glycogen synthase kinase-3beta. Mol Cancer Ther 2009; 8:914-20; PMID:19372564; http://dx.doi.org/10.1158/1535-7163.MCT-08-0712
24. Kunnimalaiyaan M, Vaccaro AM, Ndiaye MA, Chen H. Inactivation of glycogen synthase kinase- 3beta, a downstream target of the raf-1 pathway, is associated with growth suppression in medullary thyroid cancer cells. Mol Cancer Ther 2007; 6:1151-8; PMID:17363508; http://dx.doi.org/10.1158/1535-7163.MCT-06-0665 (Pubitemid 46554586)
25. Lastowska M, Cullinane C, Variend S, Cotterill S, Bown N, O'Neill S, Mazzocco K, Roberts P, Nicholson J, Ellershaw C, et al.; United Kingdom Children Cancer Study Group and the United Kingdom Cancer Cytogenetics Group. Comprehensive genetic and histopathologic study reveals three types of neuroblastoma tumors. J Clin Oncol 2001; 19:3080-90; PMID:11408505 (Pubitemid 32565447)
26. Cohen P, Goedert M. GSK3 inhibitors: development and therapeutic potential. Nat Rev Drug Discov 2004; 3:479-87; PMID:15173837; http://dx.doi.org/10.1038/nrd1415 (Pubitemid 38807530)
27. Hughes K, Nikolakaki E, Plyte SE, Totty NF, Woodgett JR. Modulation of the glycogen synthase kinase-3 family by tyrosine phosphorylation. EMBO J 1993; 12:803-8; PMID:8382613 (Pubitemid 23073729)
28. Kunnimalaiyaan M, Vaccaro AM, Ndiaye MA, Chen H. Overexpression of the NOTCH1 intracellular domain inhibits cell proliferation and alters the neuroendocrine phenotype of medullary thyroid cancer cells. J Biol Chem 2006; 281:39819-30; PMID:17090547; http://dx.doi.org/10.1074/jbc. M603578200 (Pubitemid 46041785)
29. Greenblatt DY, Cayo MA, Adler JT, Ning L, Haymart MR, Kunnimalaiyaan M, Chen H. Valproic acid activates Notch1 signaling and induces apoptosis in medullary thyroid cancer cells. Ann Surg 2008; 247:1036-40; PMID:18520232; http://dx.doi.org/10.1097/SLA.0b013e3181758d0e (Pubitemid 351770425)